Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient.
Leuk Lymphoma
; 47(2): 353-6, 2006 Feb.
Article
em En
| MEDLINE
| ID: mdl-16321871
ABSTRACT
A 48-year-old male patient with follicular lymphoma, grade II, stage IV, was treated with CHOP, ESHAP and MACOP-B, resulting in partial remission. After 9 months, the disease progressed and several chemotherapy agents, including three courses of rituximab combined with etoposide, sobuzoxane or methotrexate, only resulted in a stable disease response. However, the fourth course of rituximab combined with a small dose of melphalan produced excellent results and the complete response continued for more than 15 months. It is possible that these two drugs may act synergistically.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Linfoma Folicular
/
Melfalan
/
Anticorpos Monoclonais
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article